According to the European Society of Liver Diseases PBC guidelines,[48] the main tests included biochemical evidence of cholestasis (mainly elevated alkaline phosphatase/glutamyl transpeptidase); antimitochondrial antibodies (especially the M2 subtype) and other specific antinuclear autoantibodies (including anti-sp100 or gp210); magnetic resonance cholangiopancreatography and magnetic resonance elastography; and liver biopsy pathology. Here, SP100 is linked to liver disorder.